Literature DB >> 31571279

The movement disorder society nonmotor rating scale: Initial validation study.

K Ray Chaudhuri1, Anette Schrag2, Daniel Weintraub3,4, Alexandra Rizos1, Carmen Rodriguez-Blazquez5, Eugenia Mamikonyan3, Pablo Martinez-Martin5.   

Abstract

BACKGROUND: The Movement Disorder Society-sponsored Nonmotor Rating Scale is an update of the existing Parkinson's disease Nonmotor Symptoms Scale modified to address some limitations in Nonmotor Symptoms Scale scoring, structure, and symptom coverage.
METHODS: PD patients were recruited from movement disorder centers in an international, multicenter study. The Movement Disorder Society Nonmotor Rating Scale, consisting of 13 domains plus a subscale for nonmotor fluctuations, was rater administered, along with the Nonmotor Symptoms Scale and other clinical assessments. Standard reliability and validity testing were conducted.
RESULTS: Four hundred and two PD patients were recruited (mean age ± standard deviation, 67.42 ± 9.96 years; mean age at PD onset ± standard deviation, 59.27 ± 10.67 years; median Hoehn and Yahr stage 2 (interquartile range 2-3). Data quality was satisfactory for all Movement Disorder Society Nonmotor Rating Scale domains except sexual (6.7% missing data). There were no floor or ceiling effects for the Movement Disorder Society Nonmotor Rating Scale and nonmotor fluctuations total score; domains had no ceiling effects, but some floor effects (13.5%-83.5%). The Movement Disorder Society Nonmotor Rating Scale and nonmotor fluctuations total score internal consistency were acceptable (average Cronbach's alpha, 0.66 and 0.84, respectively); interrater reliability was excellent (intraclass correlation coefficient, >0.95); for test-retest reliability, the intraclass correlation coefficient was 0.84 for the Movement Disorder Society Nonmotor Rating Scale and 0.70 for Movement Disorder Society nonmotor fluctuations total score, and precision was excellent for the Movement Disorder Society Nonmotor Rating Scale (standard error of measurement, 25.30) and fair for nonmotor fluctuations (standard error of measurement, 7.06). Correlations between Movement Disorder Society Nonmotor Rating Scale score and the corresponding Nonmotor Symptoms Scale and Movement Disorder Society UPDRS scores were high. There were no significant sex or age effects. The Movement Disorder Society Nonmotor Rating Scale score increased with increasing PD duration, disease severity, and PD medication dose (all P < 0.001).
CONCLUSIONS: The Movement Disorder Society Nonmotor Rating Scale is a valid measure for measuring the burden of a wide range of Nonmotor Rating Scale scores, including nonmotor fluctuations, in PD patients.
© 2019 International Parkinson and Movement Disorder Society. © 2019 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; movement disorders; nonmotor fluctuations; nonmotor symptoms; scales

Mesh:

Year:  2019        PMID: 31571279      PMCID: PMC7037759          DOI: 10.1002/mds.27862

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  35 in total

1.  What sample sizes for reliability and validity studies in neurology?

Authors:  Jeremy C Hobart; Stefan J Cano; Thomas T Warner; Alan J Thompson
Journal:  J Neurol       Date:  2012-06-24       Impact factor: 4.849

Review 2.  New clinical trials for nonmotor manifestations of Parkinson's disease.

Authors:  Anette Schrag; Anna Sauerbier; Kallol Ray Chaudhuri
Journal:  Mov Disord       Date:  2015-09-15       Impact factor: 10.338

3.  The Good Clinical Practice guideline: a bronze standard for clinical research.

Authors:  David A Grimes; David Hubacher; Kavita Nanda; Kenneth F Schulz; David Moher; Douglas G Altman
Journal:  Lancet       Date:  2005 Jul 9-15       Impact factor: 79.321

4.  Quality criteria were proposed for measurement properties of health status questionnaires.

Authors:  Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2006-08-24       Impact factor: 6.437

5.  EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.

Authors:  Haidar S Dafsari; Pablo Martinez-Martin; Alexandra Rizos; Maja Trost; Maria Gabriela Dos Santos Ghilardi; Prashanth Reddy; Anna Sauerbier; Jan Niklas Petry-Schmelzer; Milica Kramberger; Robbert W K Borgemeester; Michael T Barbe; Keyoumars Ashkan; Monty Silverdale; Julian Evans; Per Odin; Erich Talamoni Fonoff; Gereon R Fink; Tove Henriksen; Georg Ebersbach; Zvezdan Pirtošek; Veerle Visser-Vandewalle; Angelo Antonini; Lars Timmermann; K Ray Chaudhuri
Journal:  Mov Disord       Date:  2019-02-04       Impact factor: 10.338

6.  Satisfaction with Life Scale (SLS-6): First validation study in Parkinson's disease population.

Authors:  Leire Ambrosio; Mari Carmen Portillo; Carmen Rodriguez-Blazquez; Juan Carlos Martínez-Castrillo; Mayela Rodriguez-Violante; Marcos Serrano-Dueñas; Víctor Campos-Arillo; Nelida Susana Garretto; Tomoko Arakaki; Mario Álvarez; Ivonne Pedroso-Ibáñez; Ana Carvajal; Pablo Martinez-Martin
Journal:  Parkinsonism Relat Disord       Date:  2016-02-15       Impact factor: 4.891

Review 7.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

Authors:  Claire L Tomlinson; Rebecca Stowe; Smitaa Patel; Caroline Rick; Richard Gray; Carl E Clarke
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

8.  Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).

Authors:  Claudia Trenkwalder; Bryan Kies; Monika Rudzinska; Jennifer Fine; Janos Nikl; Krystyna Honczarenko; Peter Dioszeghy; Dennis Hill; Tim Anderson; Vilho Myllyla; Jan Kassubek; Malcolm Steiger; Marco Zucconi; Eduardo Tolosa; Werner Poewe; Erwin Surmann; John Whitesides; Babak Boroojerdi; Kallol Ray Chaudhuri
Journal:  Mov Disord       Date:  2010-11-18       Impact factor: 10.338

9.  Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.

Authors:  Werner Poewe; K Ray Chaudhuri; Lars Bergmann; Angelo Antonini
Journal:  Neurodegener Dis Manag       Date:  2018-12-14

10.  Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.

Authors:  K Ray Chaudhuri; A Antonini; W Z Robieson; O Sanchez-Soliño; L Bergmann; W Poewe
Journal:  Eur J Neurol       Date:  2018-12-26       Impact factor: 6.089

View more
  19 in total

1.  Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search.

Authors:  Gareth Morinan; Robert A Hauser; Anette Schrag; Jingxuan Tang; Jonathan O'Keeffe
Journal:  Parkinsons Dis       Date:  2022-06-07

Review 2.  Diagnosis and Management of Pain in Parkinson's Disease: A New Approach.

Authors:  Veit Mylius; Jens Carsten Möller; Stephan Bohlhalter; Daniel Ciampi de Andrade; Santiago Perez Lloret
Journal:  Drugs Aging       Date:  2021-07-05       Impact factor: 3.923

Review 3.  Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Authors:  Daniel Weintraub
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 4.  Parkinson disease-associated cognitive impairment.

Authors:  Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub
Journal:  Nat Rev Dis Primers       Date:  2021-07-01       Impact factor: 52.329

5.  Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the MDS-NMS.

Authors:  Carmen Rodriguez-Blazquez; Anette Schrag; Alexandra Rizos; K Ray Chaudhuri; Pablo Martinez-Martin; Daniel Weintraub
Journal:  Mov Disord Clin Pract       Date:  2020-12-21

6.  Characterization of Gastrointestinal Symptom Type and Severity in Parkinson's Disease: A Case-Control Study in an Australian Cohort.

Authors:  Jade E Kenna; Megan C Bakeberg; Anastazja M Gorecki; Alfred Chin Yen Tay; Samantha Winter; Frank L Mastaglia; Ryan S Anderton
Journal:  Mov Disord Clin Pract       Date:  2021-01-05

Review 7.  The neuropsychiatry of Parkinson's disease: advances and challenges.

Authors:  Daniel Weintraub; Dag Aarsland; Kallol Ray Chaudhuri; Roseanne D Dobkin; Albert Fg Leentjens; Mayela Rodriguez-Violante; Anette Schrag
Journal:  Lancet Neurol       Date:  2022-01       Impact factor: 44.182

8.  Alexithymia Is Associated with Reduced Quality of Life and Increased Caregiver Burden in Parkinson's Disease.

Authors:  Martin Klietz; Theresa Schnur; Simon C Drexel; Florian Lange; Lejla Paracka; Meret K Huber; Dirk Dressler; Günter U Höglinger; Florian Wegner
Journal:  Brain Sci       Date:  2020-06-24

Review 9.  Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis.

Authors:  Yareth Gopar-Cuevas; Ana P Duarte-Jurado; Rosa N Diaz-Perez; Odila Saucedo-Cardenas; Maria J Loera-Arias; Roberto Montes-de-Oca-Luna; Humberto Rodriguez-Rocha; Aracely Garcia-Garcia
Journal:  Mol Neurobiol       Date:  2021-08-05       Impact factor: 5.590

10.  Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life.

Authors:  D Santos García; T De Deus Fonticoba; J M Paz González; C Cores Bartolomé; L Valdés Aymerich; J G Muñoz Enríquez; E Suárez; S Jesús; M Aguilar; P Pastor; L L Planellas; M Cosgaya; J García Caldentey; N Caballol; I Legarda; J Hernández Vara; I Cabo; L López Manzanares; I González Aramburu; M A Ávila Rivera; M J Catalán; V Nogueira; V Puente; J M García Moreno; C Borrué; B Solano Vila; M Álvarez Sauco; L Vela; S Escalante; E Cubo; F Carrillo Padilla; J C Martínez Castrillo; P Sánchez Alonso; M G Alonso Losada; N López Ariztegui; I Gastón; J Kulisevsky; M Blázquez Estrada; M Seijo; J Rúiz Martínez; C Valero; M Kurtis; O de Fábregues; J González Ardura; C Ordás; L López Díaz; P Mir; P Martinez-Martin
Journal:  Parkinsons Dis       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.